Citius Pharmaceuticals, Inc. short interest in 2021
In 2021, Citius Pharmaceuticals, Inc.'s disclosed short interest ran from 2.04% of shares outstanding on 15 Jan 2021 to 8.32% on 31 Dec 2021, a change of +6.28 percentage points. The year's high was 15.79% on 30 Jun 2021 and its low 2.04% on 15 Jan 2021, averaging 9.32% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.64 days on 30 Nov 2021. Full history: Citius Pharmaceuticals, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2021 in figures
- Start of year
- 2.04% (15 Jan 2021)
- End of year
- 8.32% (31 Dec 2021)
- Change
- +6.28 pp
- High
- 15.79% (30 Jun 2021)
- Low
- 2.04% (15 Jan 2021)
- Average
- 9.32%
- Highest days to cover
- 7.64 (30 Nov 2021)
- SEC filings marked
- 7
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 2.04% | 1.66 | |
| 29 Jan 2021 | 4.35% | 1.39 | |
| 12 Feb 2021 | 5.03% | 1.00 | 10-Q filed |
| 14 May 2021 | 10.76% | 1.98 | 10-Q filed, results (8-K) |
| 28 May 2021 | 11.68% | 4.35 | |
| 15 Jun 2021 | 11.25% | 1.73 | |
| 30 Jun 2021 | 15.79% | 1.18 | |
| 15 Jul 2021 | 12.49% | 1.09 | |
| 30 Jul 2021 | 10.75% | 5.15 | |
| 13 Aug 2021 | 9.38% | 5.38 | 10-Q filed, results (8-K) |
| 31 Aug 2021 | 8.88% | 3.91 | |
| 15 Sep 2021 | 9.87% | 4.20 | |
| 30 Sep 2021 | 9.91% | 6.82 | |
| 15 Oct 2021 | 9.71% | 7.02 | |
| 29 Oct 2021 | 9.91% | 6.20 | |
| 15 Nov 2021 | 9.22% | 7.48 | |
| 30 Nov 2021 | 8.76% | 7.64 | |
| 15 Dec 2021 | 8.98% | 6.24 | 10-K filed, results (8-K) |
| 31 Dec 2021 | 8.32% | 7.35 |
See also: Citius Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.